296 related articles for article (PubMed ID: 22922008)
21. Topical treatment of corneal alkali burns with Gly-thymosin β
Zhang W; Nie L; Du L; Chen W; Wu Z; Jin Y
Burns; 2017 Dec; 43(8):1742-1747. PubMed ID: 28602595
[TBL] [Abstract][Full Text] [Related]
22. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone.
Hoffart L; Matonti F; Conrath J; Daniel L; Ridings B; Masson GS; Chavane F
Clin Exp Ophthalmol; 2010 May; 38(4):346-52. PubMed ID: 21077280
[TBL] [Abstract][Full Text] [Related]
24. Involvement of NADPH oxidases in alkali burn-induced corneal injury.
Gu XJ; Liu X; Chen YY; Zhao Y; Xu M; Han XJ; Liu QP; Yi JL; Li JM
Int J Mol Med; 2016 Jul; 38(1):75-82. PubMed ID: 27221536
[TBL] [Abstract][Full Text] [Related]
25. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
26. The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model.
Mello GR; Pizzolatti ML; Wasilewski D; Santhiago MR; Budel V; Moreira H
Clinics (Sao Paulo); 2011; 66(8):1443-50. PubMed ID: 21915498
[TBL] [Abstract][Full Text] [Related]
27. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
28. Sustained Subconjunctival Delivery of Infliximab Protects the Cornea and Retina Following Alkali Burn to the Eye.
Zhou C; Robert MC; Kapoulea V; Lei F; Stagner AM; Jakobiec FA; Dohlman CH; Paschalis EI
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):96-105. PubMed ID: 28114570
[TBL] [Abstract][Full Text] [Related]
29. AIP1 suppresses neovascularization by inhibiting the NOX4-induced NLRP3/NLRP6 imbalance in a murine corneal alkali burn model.
Li Q; Hua X; Li L; Zhou X; Tian Y; Deng Y; Zhang M; Yuan X; Chi W
Cell Commun Signal; 2022 May; 20(1):59. PubMed ID: 35524333
[TBL] [Abstract][Full Text] [Related]
30. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
31. Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-β1/ERK pathways regulation.
Shin YJ; Hyon JY; Choi WS; Yi K; Chung ES; Chung TY; Wee WR
Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4452-8. PubMed ID: 23716625
[TBL] [Abstract][Full Text] [Related]
32. [Experimental study on the treatment of corneal melting after alkali burn with GM 6001].
Liu H; Zhang W; Pan Z; Wu Y
Zhonghua Yan Ke Za Zhi; 2002 Sep; 38(9):539-42. PubMed ID: 12410973
[TBL] [Abstract][Full Text] [Related]
33. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
Kim EK; Kong SJ; Chung SK
Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
[TBL] [Abstract][Full Text] [Related]
35. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis.
Dan L; Shi-long Y; Miao-li L; Yong-ping L; Hong-jie M; Ying Z; Xiang-gui W
Curr Eye Res; 2008 Aug; 33(8):653-60. PubMed ID: 18696340
[TBL] [Abstract][Full Text] [Related]
37. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N
Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257
[TBL] [Abstract][Full Text] [Related]
38. Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization.
Lopez ES; Rizzo MM; Croxatto JO; Mazzolini G; Gallo JE
Cancer Chemother Pharmacol; 2011 Mar; 67(3):723-8. PubMed ID: 20857116
[TBL] [Abstract][Full Text] [Related]
39. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
40. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
